Mounting premium pressures contributed to the determination.
, Aduhelm is a monoclonal antibody, a “man-made protein that targets a sticky substance in the brain, called amyloid beta, which some scientists believe causes the memory-robbing disease.”
Specifically, the drug is designed to trigger an immune response that reduces the formation and build-up of amyloid plaques, the newspaper reported.from the Centers for Medicare and Medicaid Services means that patients taking Aduhelm will have to participate in research efforts to assess the drug’s effectiveness. The ruling will not be finalized until the spring, however, following a mandated public comment period and continued evaluation by the health agency.
Meanwhile, Biogen already slashed the price of Aduhelm from $56,000 annually to $28,200, but the price reduction came after the drug’s launch price forced CMS to to increase its monthly “Part B” premium for outpatient care by $22, the largest-ever dollar-amount increase in the program’s history. “With the 50% price drop of Aduhelm on Jan. 1, there is a compelling basis for CMS to reexamine the previous recommendation,” Health and Human Services Secretary Xavier Becerra said in a statement issued Monday.
To learn more about Aduhelm, what Medicare is doing to address the issue and how those decisions affect premiums,
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Lire la suite »
Medicare proposes to cover controversial Alzheimer's drug with restrictionsMedicare proposes covering a costly and controversial Alzheimer's drug, with some restrictions. It could have vast consequences for patients and enrollees.
Lire la suite »
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Lire la suite »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Lire la suite »
Medicare told to reassess premium hike for Alzheimer's drugHealth secretary orders Medicare to reassess a big premium increase facing millions of seniors this year, attributed in large part to a pricey new Alzheimer's drug with questionable benefits.
Lire la suite »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Lire la suite »